Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 2074-2077

  Valitalo, Pyry A J ^a   Van Den Anker, John N ^b,c,d   Allegaert, Karel ^e   De Cock, Roosmarijn F W ^a   De Hoog, Matthijs ^d   Simons, Sinno H P ^d   Mouton, Johan W ^d   Knibbe, Catherijne A J ^a,d,f  

^a LEIDEN UNIVERSITY   (Netherlands)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Aminoglycosides; NONMEM; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

GENTAMICIN; TOBRAMYCIN;

AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; HUMAN; MONTE CARLO METHOD; NEPHROTOXICITY; NEWBORN; OTOTOXICITY; PRACTICE GUIDELINE; PREMATURITY; RECOMMENDED DRUG DOSE; TERM BIRTH;

EID: 84936936980     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv052     Document Type: Article

References (18)

1. Dutch Knowledge Centre for Pharmacotherapy in Children. Dutch National Formulary for Children/Kinderformularium. http://www.kinderformularium.nl/.
2. Paediatric Formulary Committee. British National Formulary for Children. London: BMJ Group, 2009.
3. Pickering LK, Baker CJ, Kimberlin DW. Red Book: 2012 Report of the Committee on Infectious Diseases. American Academy of Pediatrics, 2012.
4. Young TE. Neofax. Montvale: Thomson Reuters, 2011.
5. De Hoog M, Schoemaker RC, Mouton JW et al. Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther 1997; 62: 392-9.
6. Nielsen EI, Sandströ M, Honoré PH et al. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet 2009; 48: 253-63.
7. De Cock RFW, Allegaert K, Schreuder MFet al.Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet 2012; 51: 105-17.
8. De Cock RFW, Allegaert K, Sherwin CMT et al. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res 2014; 31: 754-67.
9. Drusano GL, Ambrose PG, Bhavnani SM et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45: 753-60.
10. Sherwin CMT, McCaffrey F, Broadbent RS et al. Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. J Pharm Pharmacol 2009; 61: 465-71.
11. Beal SL, Sheiner LB, Boeckmann AJ et al. NONMEM Users Guides. Ellicott City: Icon Development Solutions, 2013.
12. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria, 2014. http://www.R-project.org.
13. Smith CR, Lipsky JJ, Laskin OL et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. New Engl J Med 1980; 302: 1106-9.
14. van Maarseveen E, van Buul-Gast M-C, Abdoellakhan R et al. Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients. J Antimicrob Chemother 2014; 69: 2581-3.
15. Begg EJ, Vella-Brincat JWA, Robertshawe B et al. Eight years' experience of an extended-interval dosing protocol for gentamicin in neonates. J Antimicrob Chemother 2009; 63: 1043-9.
16. Labovitz E, Levison ME, Kaye D. Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother 1974; 6: 465-70.
17. Freeman CD, Strayer AH. Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy 1996; 16: 1093-102.
18. Wong E, Taylor Z, Thompson J et al. A simplified gentamicin dosing chart is quicker and more accurate for nurse verification than the BNFc. Arch Dis Child 2009; 94: 542-5.